Serotonin and melatonin do not play a prominent role in the growth of prostate cancer cell lines

Urologia Internationalis

Volumn 84, Issue 4, 2010, Pages 452-460

  Pirozhok, I ^a   Meye, A ^a   Hakenberg, O W ^b   Fuessel, S ^a,c   Wirth, M P ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Apoptosis; Cell cycle; Cellular viability; Melatonin; Prostate cancer cell lines; Serotonin

Indexed keywords

MELATONIN; MESSENGER RNA; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 1B AGONIST; SEROTONIN 1B ANTAGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE REGULATION; CELL DEATH; CELL LEVEL; CELL SPECIFICITY; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MELATONIN; PROSTATIC NEOPLASMS; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT1B; RNA, MESSENGER; SEROTONIN; SEROTONIN ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS;

EID: 77953202215     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000296296     Document Type: Article

References (28)

1. Chung LWK, Baseman A, Assikis V, Zhau H: Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 2005; 173: 10-20.
2. Sofikerim M, Eskicorapc S, Oruç Ö, Özen H: Hormonal predictors of prostate cancer. Urol Int 2007; 79: 13-18.
3. Shi XB, Ma AH, Tepper CG, Xia L: Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate 2004; 60: 257-271.
4. Maddison LA, Huss WJ, Barrios RM, Greenberg NM: Differential expression of cell cycle regulatory molecules and evidence for a 'cyclin switch' during progression of prostate cancer. Prostate 2004; 58: 335-344.
5. Dizeyi N, Bjartell A, Nilsson E, Hansson J, Gadaleanu V: Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate 2004; 59: 328-336.
6. Dizeyi N, Bjartell A, Heldlund P, Tasken KA: Expression of serotonin receptors 2B and 4 in human prostate cancer tissue and effects of their antagonists on prostate cancer cell lines. Eur Urol 2005; 47: 895-900.
7. Cindolo L, Cantile M, Vacherot F, Terry S, de la Taille A: Neuroendocrine differentiation in prostate cancer: from lab to bedside. Urol Int 2007; 79: 287-296.
8. Froehner M, Hakenberg OW, Wirth MP: Molecular therapy in urologic oncology. Urol Int 2007; 79: 1-7.
9. Bonkhoff H, Fixemer T: Neuroendokrine Differenzierung im Prostatakarzinom. Ein unerkannter und therapierefraktärer Phänotyp. Urologe 2004; 43: 836-842.
10. di Sant'Agnese PA: Neuroendocrine differentiation in prostatic carcinoma: an update. Prostate Suppl 1998; 8: 74-79.
11. Seuwen K, Pouyssegur J: Serotonin as a growth factor. Biochem Pharmacol 1990; 39: 958-990.
12. Vicaut E, Laemmel E, Stucker O: Impact of serotonin on tumour growth. Ann Med 2000; 32: 187-194.
13. Abdul M, Anezinis PE, Logothetis CJ, Hoosein NM: Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists. Anticancer Res 1994; 14: 1215-1220.
14. Abdul M, Logothetis CJ, Hoosein NM: Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol 1995; 154: 247-250.
15. Sobel RE, Sadar MD: Cell lines used in prostate cancer research: a compendium of old and new lines - part 1. J Urol 2005; 173: 342-359.
16. Sobel RE, Sadar MD: Cell lines used in prostate cancer research: a compendium of old and new lines - part 2. J Urol 2005; 173: 360-372.
17. Bartsch C, Bartsch H: Significance of melatonin in malignant diseases (in German). Wien Klin Wochenschr 1997; 109: 722-729.
18. Karasek M, Pawlikowski M: Pineal gland, melatonin and cancer. NEL Review. Neuro Endocrinol Lett 1999; 20: 139-144.
19. Siu SWF, Lau KW, Tam PC, Shiu SY: Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity. Prostate 2002; 52: 106-122.
20. Xi S, Siu SWF, Fong SW, Shiu SYW: Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression. Prostate 2001; 46: 52-61.
21. Moretti RM, Marelli MM, Maggi R, Dondi D, Motta M, Limonta P: Antiproliferative action of melatonin on human prostate cancer LNCaP cells. Oncol Rep 2000; 7: 347-351.
22. Gilad E, Laufer M, Matzkin H, Zisapel N: Melatonin receptors in PC3 human prostate tumor cells. J Pineal Res 1999; 26: 211-220. (Pubitemid 29217237)
23. Marelli MM, Limonta R, Maggi M, Motta M, Moretti RM: Growth-inhibitory activity of melatonin on human androgen-independent DU 145 prostate cancer cell lines. Prostate 2000; 45: 238-244.
24. Schmid HP, Gregorin J, Altwein JE: Growth hormone inhibitors in prostate cancer: a systematic analysis. Urol Int 2008; 81: 17-22.
25. Yan TZ, Jin FS, Xie LP, Li LC: Relationship between glucocorticoid receptor signal pathway and androgen-independent prostate cancer. Urol Int 2008; 81: 228-233.
26. Sainz RM, Mayo JC, Tan DX, León J, Manchester L, Reiter RJ: Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate 2005; 63: 29-43.
27. Hevia D, Sainz RM, Blanco D, Quirós I, Tan DX, Rodríguez C, Mayo JC: Melatonin uptake in prostate cancer cells: intracellular transport versus simple passive diffusion. J Pineal Res 2008; 45: 247-257.
28. Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP: Therapeutic actions of melatonin in cancer: possible mechanisms. Integr Cancer Ther 2008; 7: 189-203.